— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected. — Revenues grew 137% to $48.8 million, vs. $47.6 million expected. — Global revenue for Galafold was $48.8 million. — FY19 Galafold revenue is expected to be $170 million to $180 million. Get access to timely […]
“— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected. — Revenues grew 137% to $48.8 million, vs. $47.6 million expected. — Global revenue for Galafold was $48.8 million. — FY19 Galafold revenue is expected to be $170 million to $180 million. Get access to timely […]
· November 11, 2019
— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected.
— Revenues grew 137% to $48.8 million, vs. $47.6 million expected.
— Global revenue for Galafold was $48.8 million.
— FY19 Galafold revenue is expected to be $170 million to $180 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
